Showing 2791-2800 of 5974 results for "".
- Research Finds Acne Linked with Increased Risk of Depressionhttps://practicaldermatology.com/news/research-finds-acne-linked-with-increased-risk-of-depression/2457898/In an analysis of one of the largest electronic medical records databases in the world, researchers found that patients with acne had a significantly increased risk of developing major depression, but only in the first 5 years after being diagnosed with acne.
- Prestige Beauty Industry Grows to $17.7Bhttps://practicaldermatology.com/news/prestige-beauty-industry-grows-to-177b/2457900/The US prestige beauty industry reached $17.7 billion in 2017, a six percent increase over 2016, according to global information company The NPD Group. The skincare category led in growth with a nine percent increase in sales that contributed 45 percent of t
- Intraderm Changes Alevicyn Product Name to Levicynhttps://practicaldermatology.com/news/intraderm-changes-alevicyn-product-name-to-levicyn/2457910/Intraderm's Alevicyn is getting a new name—Levicyn. The Gel formulation is now Levicyn Antipruritic Gel, the Spray Gel is now Levicyn Antipruritic SG, and the Dermal Spray is now Levicyn Antimicrobial Dermal Spray. The company notes that physicians can still write for Alevicyn d
- Revision to Launch Intellishade TruPhysicalhttps://practicaldermatology.com/news/revision-to-launch-intellishade-truphysical/2457912/Revision Skincare will be launching Intellishade® TruPhysical™, formulated with a proprietary blend of over 20 age-defying ingredients. The four-in-one moisturizer helps to correct, protect, hydrate and shield skin for a brighter, smoother complexion. According to
- Anti-IL22 Therapy May Represent New Treatment Option for Severe ADhttps://practicaldermatology.com/news/researchers-close-in-on-possible-new-treatment-for-severe-ad/2457913/New research suggests that IL-22/Th22 targeting may offer a novel treatment alternative for patients with severe atopic dermatitis (AD). The findings, which appear in the Journal of the American Academy of Dermatology, provide the first e
- Maui Derm: New Data Validates First IGA Scale for EBS Clinical Trialshttps://practicaldermatology.com/news/maui-derm-new-data-validates-first-iga-scale-for-ebs-clinical-trials/2457923/Data from an evaluation of a completed Phase 2 study of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS) validate the first disease-specific Investigator’s Global Assessment (IGA) scale, Castle Creek Pharmaceuticals (CCP) reports at Maui Derm (
- FDA Accepts Ortho Dermatologics' Filing for IDP-121 Acne Treatment In Lotion Formhttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-idp-121-acne-treatment-in-lotion-form/2457925/The FDA has accepted Ortho Dermatologics' New Drug Application for IDP-121 (tretinoin 0.05%) lotion (Altreno) with a PDUFA action date of Aug. 27, 2018. If approved, Altreno will be the first tretinoin product in lotion form rather than a gel or cream.
- AAD Issues New Guidelines for Treatment of Non-melanoma Skin Cancerhttps://practicaldermatology.com/news/aad-issues-new-guidelines-for-treatment-of-non-melanoma-skin-cancer/2457928/The American Academy of Dermatology (AAD) has addressed the growing health concern about non-melanoma skin cancers (NMSC) with the release of its guidelines of care for the management of basal cell carcinoma and cutaneous squamous cell carcinoma, published online in the Journal of the Am
- New Ceramide-Infused Skin Barrier Product Reduces Costs for Ostomy Carehttps://practicaldermatology.com/news/new-ceramide-infused-skin-barrier-product-reduces-costs-for-ostomy-care/2457929/Ostomy patients using a new type of skin barrier product infused with ceramides may experience lower costs of care, according to a randomized trial published
- Cutera Introduces Juliet and Secret RFhttps://practicaldermatology.com/news/cutera-introduces-juliet-and-secret-rf/2457930/Cutera has introduced two new devices to its laser and energy-based device offerings: Juliet™ and Secret RF